Jaguar Health (JAGX) Non-Current Debt (2014 - 2026)
Jaguar Health (JAGX) posted quarterly Non-Current Debt of $11.1 million for Q1 2026, down 39.9% year-over-year from $18.4 million in Q1 2025, and down 26.57% quarter-over-quarter from $15.1 million in Q4 2025.
Jaguar Health (JAGX) Non-Current Debt (2014 - 2026) Analysis & Trends
Jaguar Health (JAGX) has reported Non-Current Debt for 13 consecutive years, with $11.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Debt fell 39.9% year-over-year to $11.1 million; the TTM figure through Mar 2026 stood at $11.1 million (down 39.9% YoY), while the FY2025 annual figure was $15.1 million, down 35.83% from the prior year.
- Non-Current Debt declined to $11.1 million in Q1 2026 per JAGX's latest filing, from $15.1 million in the prior quarter.
- Across five years, Non-Current Debt topped out at $31.2 million in Q3 2023 and bottomed at $7.6 million in Q3 2025.
- Historically, Non-Current Debt has averaged $19.7 million across 5 years, with a median of $20.0 million in 2022.
- Annual changes were most pronounced in 2023 — Non-Current Debt soared 74.67% — and 2025, when it tumbled 64.69%.
- Jaguar Health's Non-Current Debt stood at $17.7 million in 2022, then jumped by 74.67% to $31.0 million in 2023, then decreased by 24.17% to $23.5 million in 2024, then plunged by 35.83% to $15.1 million in 2025, then fell by 26.57% to $11.1 million in 2026.
- Business Quant data shows JAGX's Non-Current Debt at $11.1 million in Q1 2026, $15.1 million in Q4 2025, and $7.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.52 Bn | 132.67 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.54 Bn | 78.55 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 65.31 Bn | 60.13 Bn | 1.37 Bn | - |
| 4 | Moderna | 61.77 Bn | 56.64 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 42.26 Bn | 37.16 Bn | 1.53 Bn | 882.16 Mn |
| 6 | Alnylam Pharmaceuticals | 31.19 Bn | 27.88 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.71 Bn | 10.31 Bn | 668.28 Mn | 360.97 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 546.77 Mn |
| 9 | Royalty Pharma | 27.35 Bn | 26.52 Bn | - | 8.96 Bn |
| 10 | Jaguar Health | 460,856.56 | -9.60 Mn | 19.11 Mn | 11.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11.08 Mn |
| Dec 31, 2025 | 15.08 Mn |
| Sep 30, 2025 | 7.65 Mn |
| Jun 30, 2025 | 10.74 Mn |
| Mar 31, 2025 | 18.43 Mn |
| Dec 31, 2024 | 23.50 Mn |
| Sep 30, 2024 | 21.66 Mn |
| Jun 30, 2024 | 21.81 Mn |
| Mar 31, 2024 | 21.72 Mn |
| Dec 31, 2023 | 30.99 Mn |
| Sep 30, 2023 | 31.16 Mn |
| Jun 30, 2023 | 16.85 Mn |
| Mar 31, 2023 | 17.54 Mn |
| Dec 31, 2022 | 17.74 Mn |
| Sep 30, 2022 | 20.01 Mn |
| Jun 30, 2022 | 23.36 Mn |
| Mar 31, 2022 | 24.78 Mn |
| Dec 31, 2021 | 25.02 Mn |
| Sep 30, 2021 | 24.93 Mn |
| Jun 30, 2021 | 24.20 Mn |